Don't pay just to have an ISA. Find out more
(PYC.L) Physiomics PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 16-03-10 | RNS |
|
|
RNS Number : 5973I Physiomics PLC 16 March 2010 Physiomics Plc ("Physiomics" or "the Company") Physiomics to collaborate with Sareum, the ICR and CRT on cancer drug development programme Physiomics (AIM: PYC), the Oxford, UK based systems biology company, and Sareum Holdings plc (AIM: SAR) are pleased to announce that they have signed an agreement in which Physiomics provides in silico simulations to support Sareum's cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT). Physiomics will use its modelling expertise in biological processes to simulate the effects of cancer drugs in living systems. The research programme will focus on finalizing dose schedules for a research program compound in combination with a marketed chemotherapeutic. This work will take approximately three months to complete, and will be funded from the proceeds of a commercial deal for the molecule. Dr Christophe Chassagnole, COO of Physiomics, said: 'We are extremely pleased to start a research collaboration with such renowned partners in the field of cancer research. Our growing list of partners is a testimony to the potential of our technology to answer a key question in cancer drug development: How to find the optimal drug schedule and combination.' Professor Paul Workman, Director of the Cancer Research UK Centre for Cancer Therapeutics at the ICR, said: "We are delighted to be working with Physiomics to combine their technology with our drug discovery expertise. This collaboration supports the ICR's overall strategy of working in partnership with other leading organisations to accelerate the delivery of new and more effective drugs to cancer patients." Dr Tim Mitchell, CEO of Sareum, said: "We are very pleased to be working with Physiomics and expect their expertise will provide us with a superior drug dose schedule and add extra value to the programme licensing package." Enquiries: Physiomics plc Dr Christophe Chassagnole, COO +44 (0)1865 784980 WH Ireland Limited Katy Mitchell +44 (0)161 832 2174 Information on Physiomics plc Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million. Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The models are used to optimise compound design, as well as to design drug schedules and combination therapies. Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com The Institute of Cancer Research (ICR)
· The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe
· As a college of the University of London, the ICR also provides postgraduate higher education of international distinction · Over its 100-year history, the ICR's achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic cause of cancer and isolating more cancer-related genes than any other organisation in the world
For more information visit www.icr.ac.uk Information on Cancer Research Technology Limited Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Information on Sareum Holdings plc Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage. Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk SystemCell® is a registered trademark of Physiomics plc 1Tufts Centre Impact Report 2002 This information is provided by RNS The company news service from the London Stock Exchange END
MSCBUGDXBBBBGGU More |
||
| 01-03-10 | RNS |
|
|
RNS Number : 7363H Physiomics PLC 01 March 2010 Physiomics plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2009 Oxford, UK, 1 March 2010: The Board of Physiomics plc (AIM:PYC), a European systems biology company, today announces the financial results for the six months ended 31 December 2009. Physiomics plc is a computational systems biology services company, applying simulationssupporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Highlights during the period from 1 July 2009 to 31 December 2009 (and comparative period to 31 December 2008): Financial Highlights: · Total revenue of £116,892, (2008: £210,624), · Loss after tax of £113,070, (2008: Profit after tax £2,922)
· August and December 2009: Conversion into equity of all remaining loan note liabilities of £63,500 Operational Highlights:
· Completion of the TEMPO programme with the addition of chronotherapy to our modelling expertise. This new approach has the potential to improve the performance of standard drugs, extending their useful life as well as reducing the toxicity to the patient. · Collaboration with the Institute of Life Science (ILS) of Swansea University, update on poster presented at the 2009 AACREORTC-NCI "Molecular Targets and Cancer Therapeutics" Conference (16 November 2009). Using the Physiomics cell population simulator SystemCell® on the "Blue C" high performance computer at the ILS, it was possible to reproduce the effects of an anti cancer agent measured using conventional lab methods. · New developments of our stand-alone simulation platform ("ModelPlayer®") and our SystemCell* platform, including enhanced capabilities for the simulation of anti cancer drugs combinations and schedules. Dr Paul Harper, Chairman of Physiomics commented: The six months to December has been quiet commercially with revenues of £116,892 compared to revenues of £210,624 for the same period last year. This has resulted in a loss of £113,070 in the first half compared with a small profit for the corresponding period last year. We also took steps to convert both loan notes, with the consequent improvement in our balance sheet and the removal of a significant uncertainty in the business. Physiomics technology is used by the pharma and biotech companies to aid their drug discovery programmes. Whilst we have been in discussion with a number of major players in the sector, these discussions have become protracted. A number of such companies are reducing head-count by several thousand staff world wide. The Directors believe this has had an impact primarily on research and development in these businesses resulting in the temporary freezing of budgets, a pause whilst R&D strategies are re-visited and in some cases key staff with which we have been negotiating programmes have been lost. Whilst this is a temporary phenomenon, it has impacted on the timings we normally allow for the signing of new contracts. We had anticipated some impact and in the last Chairman's statement I had indicated that we would expect a flat 2009/10 in terms of revenue generation. The Board and senior research team concluded that this was an opportunity to consolidate the benefits of an intensive research and development effort to add new and unique functionality to our platform and to establish a strategy for rolling this out to the Industry. This was one of the principal drivers for seeking new funding and we raised more than £1.1m net of costs. Meanwhile we are working hard to bring a number of discussions with potential clients to a satisfactory conclusion. Business development activities are opening up potential new opportunities as well as pursuing on-going discussions. We are also exploring a new business model that has the potential to increase our access to clients and new business on a global basis. We hope to bring these discussions to a satisfactory conclusion before the end of H2 2010. The business development activities are driven initially by engaging the attention of potential client companies, explaining what our SystemCell® model can do for them and by providing convincing evidence that we can achieve what we claim for our technology. The new funds raised from the placement are being used to recruit a full time business development specialist who can open doors and create the opportunities for the technical team to explain how the modelling process can speed up and enhance drug discovery. The revenues that we generate are used mainly to add additional functionality to our SystemCell® platform to provide a broader and more comprehensive service to client companies. If these companies are to use the new features of SystemCell® then they must be confident that the data being produced and that the decisions made using that data are soundly based. Large sums of drug discovery cash and time can be wasted if the data is flawed. We are using some of our new cash to fund an accelerated programme of validation experiments where we show that our modelling approach is capable of predicting outcomes as effectively as tried and tested in vitro and in vivo methods used at present. We aim to show, for example that modelling the dosing of two cancer drugs used in combination will provide optimal dosing schedules. We are able to simulate thousands of dosing scenarios, well beyond anything which conventional experimentation is capable of doing, in just a few weeks, using a super computer to make the task more manageable. Add to this the use of our chronotherapy model and we move into a position where we can address much more complex modelling studies and drive the excellence of drug discovery science to a new level. There is a trend in the industry to move away from small molecule drugs in favour of advanced biologicals based upon antibodies, recombinant proteins and so on. Herceptin, which has featured in the press over recent months, is a good example of this trend. The recent development of the SystemCell® platform has the potential to model the activity of these complex molecules as effectively as conventional anti-cancer drugs. By the third quarter of this calendar year we expect to have accrued, and submitted for publication, validation data needed to convince the pharma industry that Physiomics can provide them with a unique competitive edge in their oncology programmes. We successfully developed our ModelPlayer* system as another route by which we might commercialise our technology. This is a much simplified version of our modelling software that can be used by research scientists on their PCs. Each version is customised to a particular application and we generate licensing revenues from this activity without disclosing our code. Outlook We are using our intellectual and financial resources to add functionality to the SystemCell® platform and to provide the validation evidence that will convince potential client companies that our approach to modelling can improve their development process whilst saving both time and cost. This represents a powerful incentive to adopt the modelling approach. Not only will our increased functionality make our offering more attractive but we are hoping to be able to announce a new business development paradigm that will improve our ability to access client companies globally. Whilst these benefits are unlikely to influence revenue generation in H2, we look forward further growth in our business in the next fiscal period. Dr Paul Harper Non-executive Chairman 1 March 2010 Physiomics plc Unaudited Income Statement for the half year ended 31 December 2009
attributable to equity shareholders
Earnings (loss) per share
(pence)
Physiomics plc
Unaudited Balance Sheet as at 31
December 2009
Non current assets
34 40 37
Current assets
Current liabilities
-281 -317 -361
Non current liabilities
Capital and reserves
Physiomics plc Statement of changes in equity for the half year ended 31 December 2009
Physiomics plc Unaudited Cash Flow Statement for the half year ended 31 December 2009
Cash flows from operating
activities:
receivables
payables
deferred income
operating activities
Cash flows from investing
activities:
activities
financing
Cash flows from financing
activities:
capital (net of costs)
related parties
activities
equivalents
beginning of period
end of period Physiomics plc Notes to the Interim Financial Statements 1. General information Physiomics plc is a public limited company ("the Company") incorporated in England & Wales under the Companies Act 1985 (registration number 4225086). The Company is domiciled in the United Kingdom and its registered address is The Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA. The Company's ordinary shares are traded on the AIM Market of the London Stock Exchange ("AIM"). Copies of the interim report are available from the Companies website, www.physiomics-plc.com. Further copies of the Interim Report and Annual Report and Accounts may be obtained from the address above. The Company's principal activity is the provision of services to pharmaceutical companies in the area of outsourced systems and computational biology. 2. Basis of preparation The interim financial statements of the Company for the six months ended 31 December 2009, which are unaudited, have been prepared in accordance with the accounting policies set out in the annual report and accounts for the year ended 30 June 2009, which were prepared under International Financial Reporting Standards ("IFRS"). The financial information contained in the interim report does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006. The financial information for the full preceding year is based on the statutory accounts for the year ended 30 June 2009. Those accounts, upon which the auditors, Shipleys LLP, issued an unqualified audit opinion, have been delivered to the Registrar of Companies. As permitted, this interim report has been prepared in accordance with the AIM Rules for Companies and not in accordance with IAS 34 "Interim Financial Reporting" therefore it is not fully compliant with IFRS. The interim financial statements are presented in sterling and all values are rounded to the nearest thousand pounds (£'000) except when otherwise indicated. This information is provided by RNS The company news service from the London Stock Exchange END
IR KKADDCBKKKBB More |
||
| 01-03-10 | RNS |
|
|
RNS Number : 7363H Physiomics PLC 01 March 2010 Physiomics plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2009 Oxford, UK, 1 March 2010: The Board of Physiomics plc (AIM:PYC), a European systems biology company, today announces the financial results for the six months ended 31 December 2009. Physiomics plc is a computational systems biology services company, applying simulationssupporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Highlights during the period from 1 July 2009 to 31 December 2009 (and comparative period to 31 December 2008): Financial Highlights: · Total revenue of £116,892, (2008: £210,624), · Loss after tax of £113,070, (2008: Profit after tax £2,922)
· August and December 2009: Conversion into equity of all remaining loan note liabilities of £63,500 Operational Highlights:
· Completion of the TEMPO programme with the addition of chronotherapy to our modelling expertise. This new approach has the potential to improve the performance of standard drugs, extending their useful life as well as reducing the toxicity to the patient. · Collaboration with the Institute of Life Science (ILS) of Swansea University, update on poster presented at the 2009 AACREORTC-NCI "Molecular Targets and Cancer Therapeutics" Conference (16 November 2009). Using the Physiomics cell population simulator SystemCell® on the "Blue C" high performance computer at the ILS, it was possible to reproduce the effects of an anti cancer agent measured using conventional lab methods. · New developments of our stand-alone simulation platform ("ModelPlayer®") and our SystemCell* platform, including enhanced capabilities for the simulation of anti cancer drugs combinations and schedules. Dr Paul Harper, Chairman of Physiomics commented: The six months to December has been quiet commercially with revenues of £116,892 compared to revenues of £210,624 for the same period last year. This has resulted in a loss of £113,070 in the first half compared with a small profit for the corresponding period last year. We also took steps to convert both loan notes, with the consequent improvement in our balance sheet and the removal of a significant uncertainty in the business. Physiomics technology is used by the pharma and biotech companies to aid their drug discovery programmes. Whilst we have been in discussion with a number of major players in the sector, these discussions have become protracted. A number of such companies are reducing head-count by several thousand staff world wide. The Directors believe this has had an impact primarily on research and development in these businesses resulting in the temporary freezing of budgets, a pause whilst R&D strategies are re-visited and in some cases key staff with which we have been negotiating programmes have been lost. Whilst this is a temporary phenomenon, it has impacted on the timings we normally allow for the signing of new contracts. We had anticipated some impact and in the last Chairman's statement I had indicated that we would expect a flat 2009/10 in terms of revenue generation. The Board and senior research team concluded that this was an opportunity to consolidate the benefits of an intensive research and development effort to add new and unique functionality to our platform and to establish a strategy for rolling this out to the Industry. This was one of the principal drivers for seeking new funding and we raised more than £1.1m net of costs. Meanwhile we are working hard to bring a number of discussions with potential clients to a satisfactory conclusion. Business development activities are opening up potential new opportunities as well as pursuing on-going discussions. We are also exploring a new business model that has the potential to increase our access to clients and new business on a global basis. We hope to bring these discussions to a satisfactory conclusion before the end of H2 2010. The business development activities are driven initially by engaging the attention of potential client companies, explaining what our SystemCell® model can do for them and by providing convincing evidence that we can achieve what we claim for our technology. The new funds raised from the placement are being used to recruit a full time business development specialist who can open doors and create the opportunities for the technical team to explain how the modelling process can speed up and enhance drug discovery. The revenues that we generate are used mainly to add additional functionality to our SystemCell® platform to provide a broader and more comprehensive service to client companies. If these companies are to use the new features of SystemCell® then they must be confident that the data being produced and that the decisions made using that data are soundly based. Large sums of drug discovery cash and time can be wasted if the data is flawed. We are using some of our new cash to fund an accelerated programme of validation experiments where we show that our modelling approach is capable of predicting outcomes as effectively as tried and tested in vitro and in vivo methods used at present. We aim to show, for example that modelling the dosing of two cancer drugs used in combination will provide optimal dosing schedules. We are able to simulate thousands of dosing scenarios, well beyond anything which conventional experimentation is capable of doing, in just a few weeks, using a super computer to make the task more manageable. Add to this the use of our chronotherapy model and we move into a position where we can address much more complex modelling studies and drive the excellence of drug discovery science to a new level. There is a trend in the industry to move away from small molecule drugs in favour of advanced biologicals based upon antibodies, recombinant proteins and so on. Herceptin, which has featured in the press over recent months, is a good example of this trend. The recent development of the SystemCell® platform has the potential to model the activity of these complex molecules as effectively as conventional anti-cancer drugs. By the third quarter of this calendar year we expect to have accrued, and submitted for publication, validation data needed to convince the pharma industry that Physiomics can provide them with a unique competitive edge in their oncology programmes. We successfully developed our ModelPlayer* system as another route by which we might commercialise our technology. This is a much simplified version of our modelling software that can be used by research scientists on their PCs. Each version is customised to a particular application and we generate licensing revenues from this activity without disclosing our code. Outlook We are using our intellectual and financial resources to add functionality to the SystemCell® platform and to provide the validation evidence that will convince potential client companies that our approach to modelling can improve their development process whilst saving both time and cost. This represents a powerful incentive to adopt the modelling approach. Not only will our increased functionality make our offering more attractive but we are hoping to be able to announce a new business development paradigm that will improve our ability to access client companies globally. Whilst these benefits are unlikely to influence revenue generation in H2, we look forward further growth in our business in the next fiscal period. Dr Paul Harper Non-executive Chairman 1 March 2010 Physiomics plc Unaudited Income Statement for the half year ended 31 December 2009
attributable to equity shareholders
Earnings (loss) per share
(pence)
Physiomics plc
Unaudited Balance Sheet as at 31
December 2009
Non current assets
34 40 37
Current assets
Current liabilities
-281 -317 -361
Non current liabilities
Capital and reserves
Physiomics plc Statement of changes in equity for the half year ended 31 December 2009
Physiomics plc Unaudited Cash Flow Statement for the half year ended 31 December 2009
Cash flows from operating
activities:
receivables
payables
deferred income
operating activities
Cash flows from investing
activities:
activities
financing
Cash flows from financing
activities:
capital (net of costs)
related parties
activities
equivalents
beginning of period
end of period Physiomics plc Notes to the Interim Financial Statements 1. General information Physiomics plc is a public limited company ("the Company") incorporated in England & Wales under the Companies Act 1985 (registration number 4225086). The Company is domiciled in the United Kingdom and its registered address is The Magdalen Centre, Oxford Science Park, Oxford, OX4 4GA. The Company's ordinary shares are traded on the AIM Market of the London Stock Exchange ("AIM"). Copies of the interim report are available from the Companies website, www.physiomics-plc.com. Further copies of the Interim Report and Annual Report and Accounts may be obtained from the address above. The Company's principal activity is the provision of services to pharmaceutical companies in the area of outsourced systems and computational biology. 2. Basis of preparation The interim financial statements of the Company for the six months ended 31 December 2009, which are unaudited, have been prepared in accordance with the accounting policies set out in the annual report and accounts for the year ended 30 June 2009, which were prepared under International Financial Reporting Standards ("IFRS"). The financial information contained in the interim report does not constitute statutory accounts as defined in Section 435 of the Companies Act 2006. The financial information for the full preceding year is based on the statutory accounts for the year ended 30 June 2009. Those accounts, upon which the auditors, Shipleys LLP, issued an unqualified audit opinion, have been delivered to the Registrar of Companies. As permitted, this interim report has been prepared in accordance with the AIM Rules for Companies and not in accordance with IAS 34 "Interim Financial Reporting" therefore it is not fully compliant with IFRS. The interim financial statements are presented in sterling and all values are rounded to the nearest thousand pounds (£'000) except when otherwise indicated. This information is provided by RNS The company news service from the London Stock Exchange END
IR KKADDCBKKKBB More |
||
| 08-02-10 | RNS |
|
|
RNS Number : 8425G Physiomics PLC 08 February 2010 Physiomics plc (the "Company") Notice of interest The Company announces that it received notification that following a recent disposal on 5 February 2010 of 2,000,000 Ordinary Shares in the Company, Energiser Investments plc now has an interest in 29,500,004 Ordinary Shares which represents 2.95% of the current voting rights of the Company. Energiser Investments plc no longer holds a disclosable interest in the Company. Enquiries: Physiomics plc Dr Christophe Chassagnole, COO +44 (0)1865 784980 WH Ireland Limited Katy Mitchell +44 (0) 161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange END
HOLQVLFBBLFLBBB More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Thu 21:24 | ||||
|
| ||||
|
| ||||
|
I see the ask = 0
Does that mean you can buy them for nothing and sell them for 0.25 What a steel. I’ve been doing it all wrong. |
||||
| Wed 16:13 | ||||
|
| ||||
|
| ||||
|
Guys, i refrained from posting on here for many many weeks whilst all the banter was flying about precisely for the reason i stated ( to avoid being labelled a ramper ) I have openly stated my case for pyc and also tricor plc which i see both as major stars in 2010, not everyone agrees on everything and especially on penny stocks but these two have all the ingredients for great things and will release major news IMHO.
GOOD LUCK TO ALL HOLDERS HERE |
||||
| Wed 10:22 | ||||
|
| ||||
|
| ||||
|
scf430071,
Sorry I didnt mean you, I know you've been here a while. I was referring to patty 001. |
||||
| Wed 09:20 |
BUY
Re: Question
|
|||
|
| ||||
|
| ||||
|
lol. I wondered how long it would take to be accused as a supporter of SS. I've never met the guy, nor do I know anything about him or converse with him...
I just have the same positive views around this share as he does. |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...